Oxford, UK – 6 June 2013: Oxford BioMedica (“the Company”) (LSE: Oxford Biomedica), the leading gene-based biopharmaceutical company, today announces that it has appointed Nomura Code Securities Limited as its sponsor, financial adviser and broker with immediate effect. Read More
Oxford, UK – 6 June 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), the leading gene-based biopharmaceutical company, announces that Dr Stuart Naylor will step down from the Board of Oxford BioMedica and as Chief… Read More
Oxford, UK – 3 June 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), the leading gene-based biopharmaceutical company, today announces that it has voluntarily paused recruitment into the RetinoStat® Phase I, StarGen™… Read More
Oxford, UK – 16 May 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 January to 15 May 2013. Read More
– UshStat® video selected to showcase theme of “Life-changing Research” — Oxford, UK – 9 May 2013: Oxford BioMedica plc… Read More
Oxford, UK – 1 May 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), the leading gene-based biopharmaceutical company, announces that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford… Read More
— First patient treated at Velindre Cancer Centre, Wales (UK) — Oxford, UK – 7 March 2013: Oxford BioMedica plc (“Oxford BioMedica” or… Read More
Click here to download the full 2012 preliminary results statement.Click here to download the 2012 results slide deck.Click here to listen to the… Read More
Oxford, UK – 23 January 2013: Oxford BioMedica plc (LSE: Oxford Biomedica), the leading gene-based biopharmaceutical company, will be announcing its preliminary results for the twelve months ended 31 December 2012 on Wednesday, 27 February 2013. Read More
— ImaginAb acquires exclusive worldwide licence for 5T4-based imaging diagnostic — Oxford, UK and Los Angeles, CA – 29 November 2012: Oxford BioMedica (“Oxford… Read More
— Positive DSMB review of first patient cohort in UshStat® Phase I/IIa Study —— Further encouraging data from RetinoStat® and StarGen™ clinical studies —… Read More
Oxford, UK 14 November 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 July to 13 November 2012. Read More